anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Noninvasive ventilation (NIV) is a widely used and well-established treatment modality for respiratory failure. In patients with increased respiratory work of breathing, accessory muscles are commonly activated along with the diaphragm. Whereas diaphragm ultrasound has been utilized to assess outcomes of mechanical ventilation, the data on intercostal muscle ultrasound remain limited. We aimed to investigate the association between intercostal muscle thickening fraction (TF) and NIV failure in critical care patients with hypercapnic respiratory failure.
METHODS: Critical care subjects receiving NIV for hypercapnic respiratory failure were enrolled in the study. The intercostal muscle TF was measured on admission day (day 0) and the following day (day 1). NIV failure was defined as the need for invasive mechanical ventilation or death during NIV therapy.
RESULTS: A total of 158 subjects were enrolled, and 30 experienced NIV failure. Age, sex, and body mass index (BMI) were similar in the NIV success and failure groups. Acute Physiology And Chronic Health Evaluation II (APACHE II) and the Sequential Organ Failure Assessment (SOFA) scores were higher in the NIV failure group. In terms of causes of respiratory failure, the COPD exacerbation rate was higher in the NIV success group. TF was higher in the NIV failure group on both day 0 and day 1. The increased TF on the ICU admission day, with a cutoff value of 12%, was associated with NIV failure after adjusting for age, sex, BMI, APACHE II, and SOFA. Persistence of a higher TF value on both day 0 and day 1 was also associated with NIV failure risk.
CONCLUSIONS: There was a positive relation between intercostal muscle TF measured by ultrasound and NIV failure, even after adjusting for APACHE II and SOFA scores.
Language treatment will focus on improving sentence comprehension and production deficits in people who have aphasia. An experimental group will receive treatment focusing on improving sentence processing and a control/natural history group will receive no treatment. Both groups will be assessed at baseline (week 0), at week 12, and at week 24.
The de-escalating violence training intervention will be introduced before the second observation period at month 11. A refreshment training will be introduced at month 18.
PURPOSE:To secure such an apatite bone inplant that is very high in adhesive strength between an apatite sintered body outer cover and a metallic core body by pressing the outer cover containing life active glass and the core body together under heating. CONSTITUTION:Apatite is crushed into powder at 200-500 mesh in advance. An additive value of life active glass should be set to 1-99wt.% or so in making the whole body of a sintered body a criterion, if possible, 40-70wt.%. In order to secure this apatite sintered body contained with this life active glass, both elements are mixed together with their powder themselves and then they are compressed and molded in a bar, next it is sintered at a temperature of 700-1,200 deg.C, or compressed and molded in the bar form, then it is sintered at 700-1,200 deg.C as being pressed. An outer cover 2 obtained and a metallic core body 1 of a titanium alloy or the like are heated at a temperature of 800-1,000 deg.C, and pressed together under heating. As for a method of pressure- sticking, there are a hot press process pressurizing from vertical two directions and a hot isostatic press process pressurizing from all directions. In this case, it is desirable that pressure of 50kg/cm<2>-2t/cm<2> or so is added to the metallic core body.
PROBLEM TO BE SOLVED: To obtain a solid type powder make-up cosmetic capable of preventing crack in moisture molding of make-up cosmetic in which spherical powder is highly blended by blending specific powder having high aspect ratio with spherical powder. SOLUTION: This make-up cosmetic comprises a blend of powder having >=50 high aspect ratio with spherical powder. A blend amount of the powder having high aspect ratio is preferably 0.1 to 80wt.% and a blend amount of spherical powder is preferably 10-60wt.%. Mica having high aspect ratio is preferably used as the powder having high aspect. An organopolysiloxane is preferably used as the spherical powder. The solid type powder make-up cosmetic is obtained by adding a solvent to a cosmetic base to form slurry, packing the slurry into a container, removing the solvent from the slurry. Furthermore, a blend ratio of the powder having high aspect ratio to the spherical powder is preferably (1:1) to (1:5).
Hypersensitivity, including urticarial / anaphylactic reactions, have been reported after administration of Activase (e.g., laryngeal edema, rash and shock). Rare fatal outcome for hypersensitivity was reported. Angioedema has been observed during and up to 2 hours after Activase infusion in patients treated for acute ischemic stroke and acute myocardial infarction. In many cases, patients received concomitant angiotensin-converting enzyme inhibitors [see Drug Interactions (7)]. 

Monitor patients treated with Activase during and for several hours after infusion for hypersensitivity. If signs of hypersensitivity occur, e.g. anaphylactoid reaction or angioedema develops, discontinue the Activase infusion and promptly institute appropriate therapy (e.g., antihistamines, intravenous corticosteroids, epinephrine).
The invention discloses a nicotinamide ribose or mononucleotide analogue-macromolecular carrier conjugate, a preparation method and application thereof, belonging to the technical field of biological medicines. The structure of the nicotinamide ribose or nicotinamide mononucleotide analogue-macromolecular carrier conjugate is shown as a formula I. The preparation method comprises the steps of boric acid esterification of the macromolecular compound, and then reaction with nicotinamide ribose or nicotinamide mononucleotide to generate nicotinamide ribose or mononucleotide analogue-macromolecular carrier conjugate. The drug-macromolecular carrier conjugate disclosed by the invention is applied to preparation of drugs for treating senile degenerative diseases. The compound of the invention can avoid the metabolic inactivation and the in vivo quick removal of small molecule active compounds in the digestive tract, and improve the activity and the in vivo bioavailability of nicotinamide ribose or mononucleotide. The preparation method is simple, high in yield and suitable for industrial production.
Data collected by an electrophysiology catheter during an ablation procedure, such as a pulmonary vein isolation, can be visualized using an electroanatomical mapping system. The mapping system receives data points measured by the catheter, each of which includes localization information and at least one procedure metric. The system then applies an ablation procedure model to the data points. The model facilitates relating the data points to one or more anatomical features using the localization data and/or relating the data points to an ablation procedure outcome using the metric(s). This allows the system to generate map(s) of the metric(s) and output visualization(s) of the map(s). The visualization(s) can include two-dimensional schematic anatomical representation(s) of the metric(s) and/or two-dimensional representation(s) of the metric(s) versus time. Various metrics, including, but not limited to, contact angle, contact force, and catheter stability, can be visualized.
This is an open-label (all people know the identity of the intervention), randomized (the study medication is assigned by chance), comparative bridging study (a supplemental study which performs to provide data of effectiveness, safety, and dosage to compare two study medications in a new region). The study consists of 3 phases: screening phase (30 days before administration of study medication), treatment phase, and follow up phase (every 8 weeks for tumor assessment until disease progression or death, or until the study completion, whichever is earlier and every 3 months after disease progression for overall survival and for anti-tumor therapy for a minimum of 1 year). In the treatment phase, approximately 120 eligible participants will be categorized prospectively for platinum-sensitivity (sensitive versus refractory) and bulky disease (presence versus absence). Later on participants will be randomly assigned either to experimental arm (CAELYX: administer on Day 1 of each cycle) or control arm (topotecan HCl: administer on Day 1 to Day 5 of each cycle). Treatment will continue until disease progression occurs and may continue for at least 2 cycles after confirmed complete response (disappearance of all target lesions). On average, it is expected that participants will continue treatment for approximately 3 to 6 cycles in experimental arm (CAELYX) or 4 to 8 cycles in Control arm (topotecan HCl). Safety evaluations will include assessment of adverse events, clinical laboratory tests, electrocardiogram, echocardiogram (or multiple gated acquisition scans), vital signs, and physical examination which will be monitored throughout the study. The total duration of the study will be approximately 23 months.
Subjects will take the study drug certolizumab for 8 weeks. They will undergo a endoscopy before study drug and then again after study is complete. The study doctor will be looking for complete closure of the peri-anal fistula identified at visit 1 after the use of certolizumab based on and endoscopic ultrasound (EUS).
Bradycardia and sinus arrest have been reported following administration of dexmedetomidine HCl to young, healthy adult volunteers with high vagal tone or following rapid intravenous or bolus administration of dexmedetomidine HCl. Bradycardia has also been reported in association with intravenous infusion of dexmedetomidine HCl. Some of these cases have resulted in fatalities. Dexmedetomidine HCl decreases sympathetic nervous system activity and has the potential to augment bradycardia induced by vagal stimuli. Elderly patients and patients with advanced heart block, severe ventricular dysfunction, hypovolemia, diabetes mellitus, and/or chronic hypertension are at increased risk of bradycardia following administration of dexmedetomidine HCl. Closely monitor heart rate and other hemodynamic parameters during administration of dexmedetomidine HCl. In patients who develop bradycardia, consider decreasing or stopping the dexmedetomidine HCl infusion; decreasing or stopping other medications that depress the sinus node function; administering anticholinergic agents (e.g., glycopyrrolate, atropine) to modify vagal tone; and/or administering pressor agents. In patients with significant cardiovascular dysfunction, more advanced resuscitative measures may be required.
A major objective in post-stroke aphasia research is to gain a deeper understanding of neuroplastic mechanisms that drive language recovery, with the ultimate goal of enhancing treatment outcomes. Subsequent to recent advances in neuroimaging techniques, we now have the ability to examine more closely how neural activity patterns change after a stroke. However, the way these neural activity changes relate to language impairments and language recovery is still debated. The aim of this review is to provide a theoretical framework to better investigate and interpret neuroplasticity mechanisms underlying language recovery in post-stroke aphasia. We detail two sets of neuroplasticity mechanisms observed at the synaptic level that may explain functional neuroimaging findings in post-stroke aphasia recovery at the network level: feedback-based homeostatic plasticity and associative Hebbian plasticity. In conjunction with these plasticity mechanisms, higher-order cognitive control processes dynamically modulate neural activity in other regions to meet communication demands, despite reduced neural resources. This work provides a network-level neurobiological framework for understanding neural changes observed in post-stroke aphasia and can be used to define guidelines for personalized treatment development.
PURPOSE:To form a solid powdery cosmetic containing uniformly dispersed constituent components, by slurrying a cosmetic base with a solvent, filling the slurry in a forming frame having openings at both sides and sucking the solvent from both openings, thereby uniformly and quickly removing the solvent from the formed cosmetic. CONSTITUTION:A forming frame 1 is fit into a frame-fitting hole 5B of a base 5 and the end face of an opening 2 is contacted to a hollow holding member 8 via a nylon mesh 16. A pushing means 15 is energized to contact a hollow holding member 14 to an end face of an opening 3 via a nylon mesh 16. A filling nozzle 18C is inserted into the filling port 1A of the forming frame 1 and a cosmetic base slurried with a solvent is forced and filled into a forming part 4. After the completion of filling, a vacuum pump 16 is started to suck the solvent in the slurry through the nylon mesh 16 and both openings 2, 3 of the molding frame 1 into the hollow holding members 8, 14. The solvent is recovered via suction ports 10, 10', exhaustion ports 6, 7 and a piping.
Small changes in diet have been shown to have an important impact on health and the risk of age-related chronic diseases, such as cardiovascular disease, diabetes, frailty and dementia. However, this knowledge has not yet been implemented into routine clinical practice, because practical tools that allow a comprehensive nutrition assessment in the clinical care setting are missing. In addition, doctors are generally not educated in giving nutritional advice to patients. In this pilot project, we aim to push forward and enable the potential of nutrition as a core primary prevention strategy for people at risk of developing chronic diseases. This will be achieved by using, as a stepping stone, the electronic 216-food-item food frequency questionnaire which was developed for the European DO-HEALTH study and was tested in over 2000 adults. The investigators want to extend this tool to not only capture the personal dietary intake, but also to produce an immediate report, comparing the personal diet to the Mediterranean and MIND diet patterns and providing a patient's intake of protein and other nutrients. The report will additionally indicate the patient's diet-related, personalized risks of cardio-vascular disease, diabetes, frailty and cognitive decline, and recommend dietary changes to reduce these risks.
The "Program of Research on Integration of Services for the Maintenance of Autonomy" (PRISMA-7) is the Ministry of Health and Social Services' reference tool for the assessment of older ED users in Quebec (Canada). PRISMA-7 has been initially designed to screen disability in community-dwelling older adults and has never been validated for risk for short-term adverse events in older ED users. "Emergency room evaluation and recommendations" (ER2) is another clinical tool which is currently evaluated in Quebec. Compared to PRISMA-7, ER2 has been especially designed for assessing risk for short-term ED adverse events. No study has compared PRISMA-7 and ER2 risk for short-term adverse events. We hypothesised that ER2 could be a better prognostic tool compared to PRISMA-7 for long length of stay in ED and hospital stay, and hospital admission because it was designed and validated for this specific goal. The study aims to 1) examine and compared PRISMA-7 and ER2 risk for long length of ED and hospital stay and hospital admission, and 2) to establish their performance criteria (i.e., sensitivity, specificity, positive predictive value, negative predictive value, likelihood ratios) for these three short-term adverse events in older ED users.
BACKGROUND: Aphasia is a devastating consequence after stroke, affecting millions of patients each year. Studies have shown that intensive speech and language therapy (SLT) is effective in the chronic phase of aphasia. Leveraging a large single-center cohort of persons with aphasia (PWA) including patients also in the subacute phase, we assessed treatment effects of intensive aphasia therapy in a real-world setting.
METHODS: Data were collected at the Aachen aphasia ward in Germany between 2003 and 2020. Immediate treatment responses across different language domains were assessed with the Aachen Aphasia Test (AAT) using single-case psychometrics, conducted before and after 6-7 weeks of intensive SLT (10 h per week, median (IQR) dosage = 68 (61-76)). We adjusted for spontaneous recovery in subacute patients. Differential treatment effects between subgroups of chronicity and predictors of therapy response were investigated.
RESULTS: A total of 448 PWA were included (29% female, median (IQR) age = 54 (46-62) years, median (IQR) time post-onset = 11 (6-20) months) with 12% in the early subacute, 15% in the late subacute and 74% in the chronic phase of aphasia. The immediate responder rate was 59%. Significant improvements in all AAT subtests und subscales were observed hinting at broad effectiveness across language domains. The degree of therapy-induced improvement did not differ between the chronicity groups. Time post-onset, dosage of therapy and aphasia severity at the beginning of treatment were predictors of immediate treatment response.
DISCUSSION: Intensive therapy protocols for aphasia after stroke are yielding substantial responder rates in a routine clinical setting including a wide range of patients.
Cohort B will include patients who underwent HSCT with incomplete count recovery although they had ≤%10 bone marrow blasts at the time of HSCT. Crenolanib besylate maintenance therapy will start at the earliest time no sooner than 42 days but no later than 90 days after allogeneic HSCT.
A surgical system includes a surgical hub configured to be coupled to an inventory item of a facility. The inventory item includes a medical device. The surgical hub includes a processor, a memory, and a cloud-based analysis system. The memory stores instructions executable by the processor to communicate with the item of inventory. The cloud-based analysis system is coupled to the surgical hub and includes a processor and a memory coupled to the processor. The memory stores instructions executable by the processor to: receiving data associated with the inventory item, determining availability of the inventory item based on a unique identifier and system-defined constraints, generating a cloud interface for the organization, and transmitting an alert for each inventory item determined to be unavailable based on the system-defined constraints.
A system is provided for de-identifying electronic records. The system may be configured to tokenize an electronic record to produce a plurality of tokens including a first token. The system may determine whether the first token is part of one of a plurality of expressions known to include protected health information. In response to determining that the first token is not part of any one of the plurality of expressions, the system may determine, based on a blacklist of tokens known to include protected health information, whether the first token includes protected health information. In response to determining that the first token includes protected health information, the system may generate a de-identified electronic record by replacing the first token with a second token obfuscating the protected health information. Related methods and computer program products are also provided.
An osmotic delivery system for controlled delivery of a beneficial agent includes an implantable capsule containing a beneficial agent and an osmotic engine that swells on contact with water, to thereby cause the release of the beneficial agent over time. The osmotic delivery system has a membrane material that allows a controlled amount of fluid to enter from an exterior of the capsule, while preventing the compositions within the capsule from passing out of the capsule. The osmotic delivery system is designed to meet at least the operating pressures of 1000 psi. the membrane material is cast, calendered or extruded followed by machining (i.e. die-cutting, stamping or otherwise cutting to shape) to provide a uniform  non-ribbed membrane material. The capsule also includes a membrane material retaining means that is positioned at a fluid uptake end to retain the membrane material within the capsule, even under periods of high pressure.
Study procedure In each period, the subjects arrived at the clinical/unit site on the day before the commencement of the study and were randomized using Excel® 2007 to receive the test formulation followed by the reference formulation, or viceversa. No food was allowed from 10 h before until at least 4 h after drug administration. On the subsequent morning, a peripheral venous 21G catheter was inserted in the antecubital vein of the subjects and blood samples were collected (zero time). The subjects then received a single 75 mg tablet of either the test or the reference formulation, given with 250 mL water. Blood samples were collected at 0.16, 0.33, 0.5, 0.66, 0.83, 1, 1.5, 1.75, 2, 2.5, 3, 6, 8, 12, 16 and 24 h after drug administration. The blood samples were collected in coded EDTA tubes and plasma was obtained by centrifugation (2,053 g for 10 min at 5 C), after which the plasma was immediately transferred to prelabeled vials and stored at or below -70 After a week of washout, the alternative formulation was administered to the subjects and samples were drawn and analyzed as before.
This is a prospective, multicenter, non-randomized interventional study to evaluate the safety, effectiveness, and performance of Venus-Neo Surgical Aortic Valve. 155 subjects are estimated to be enrolled in this study. Total enrollment period for this trial is estimated to be 1 year. Follow-up duration is estimated to be 5 years. Overall duration of the trial is estimated to be 6 years. The trial begins with the enrollment of the first subject and ends after the last subject is exited from the trial after completing the last follow-up visit at approximately 5 years, all subjects are fully monitored, all outstanding data queries are resolved.
<P>PROBLEM TO BE SOLVED: To provide a therapeutic means for disorders where T-cells are involved or recruited.  <P>SOLUTION: The peptide affecting T-cells presumably by action on the T-cell antigen receptor is provided. The therapy of various inflammatory and autoimmune disease states involving the use of the peptide is also provided. Specifically, the peptide is useful in the treatment of disorders where T-cells are involved or recruited. The peptide is represented by the formula: A-B-C-D-E (wherein, A is absent or 1 or 2 hydrophobic amino acids; B is a positively charged amino acid; C is a peptide consisting of 3 to 5 hydrophobic amino acids; D is a positively charged amino acid; and E is absent or up to 8 hydrophobic amino acids).  <P>COPYRIGHT: (C)2005,JPO&NCIPI